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ANTICANCER DRUG-INDUCED APOPTOSIS : CHARACTEFUSATION, 
COMPARATIVE STUDY AND RESCUE IN HUMAN LEUKEMIC CELL LINES 
Apoptosis, a naturally occuring phenomena durmg development and thereafter for 
maintaining homeostasis in an organism, 1s retained by the cancerous cells and the death 
programme itself, never seems to be completely inactivated In cancer cells Cancer cells 
evolve by a process of random mutation and selection, they become progressively more 
malignant as they accumulate mutations that lmprove their abillty to survive and 
prollferate Mutations that inactivate apoptosls should therefore be advantageous to 
cancer cells However this does not happen It IS a mystery that the death programme 
always seems to be present? How do cell integrate apoptosls-promoting and apoptos~s- 
suppressing s~gnals to decide whether to h e  or die? How is the balance between cell 
dlvwon and apoptosls maintained In an adult organmn? The practical question is 
whether apoptosis-blockers will be useful in the treatment of human diseases? The most 
widely studied questlon IS how do antlcancer drugs brlng about apoptosls? Re-evaluating 
and understanding the character~stics of drug-induced apoptosis is very important not 
only to bnng in better poss~billtles of cure for cancer but also to comprehens~vely 
understand the nature of cancer b~ology Such research can also help In developing drugs 
that target apoptosis to treat cancer It also might glve us ideas for treating other cancers 
It 1s generally believed that the cytotoxicity of antitumor agents is directly correlated mth 
the amount of drug-induced cellular lesions Accordingly, biologists and oncologists have 
tned to lmprove anticancer agentltarget interactions by increasing the lntracellular dose 
of active effectors From the llterature, it can be observed that the mkchanisrn of action of 
antlcancer agents In inducing apoptos~s IS not yet h l ly  understood Hence it becomes 
necessary to charactenze drug-induced apoptosls so that a minimum correlation could be 
established for a particular drug or a group of drugs and its apoptosis-induc~ng capacity, 
and the mechanism of Induced apoptosis Scattered reports In the literature show how de 
now and salvage pathway(s) of purine and pyrimidme blosynthesis play major roles in 
antmetabohte-drug-~nduced apoptosls and its rescue Therefore, ~t appears that cell death 
commitment is controlled by both external and internal factors whlch mterfere 
downstream of drug-target interaction, leadlng to apoptosis There is urgency to 
characterize these mediators/factors involved in both cell s~gnalling and apoptosrs 
Years of cancer treatment with various drugs has brought forth the understanding that 
Intimate knowledge of drug action, drug disposition, and drug interactions is essential for 
the deslgn and application of effectwe cancer chemotherapy From the literature, it is also 
known in many cases that anticancer drug-induced apoptosis in various cell lines is 
governed by Bc12, p53 status and other anti- and pro-apoptotic geneslproteins 
To understand drug-rnduced apoptosis we have chosen a panel of leukeinlc cell lines as a 
model system to study the apoptos~s-lnducing effects of antiinetabol~tes 
fluoropyrimidmes and methotrexate This system gives us the convenience to monltor the 
effects of the drugs (in terms of apoptosis) between different cell types of leukemia 
AIM OF THE THESIS : 
Most of the drugs used in chemotherapy cause necrosis rather than apoptosis at the 
concentrations used, moreover they are not used for all cancer types Hence we dec~ded 
to characterize and compare the apoptosls-inducing capaclty of fluoropyrimidines and 
methotrexate in human leukemlc cell lines We undertook a task to study systematically 
some basic charactenstics as given below 
Most cancer cell lines have e~ther a mutated p53 gene or has an inactive p53 protetn 
or 1sp53-null Hence, we decided to find out how the drugs mduce apoptosis, In six 
p53-negat~ve human leukem~c cell lines, a p53-negative human colon carcinoma cell 
line, a p53-posit~ve mouse leukemic cell line, and a mouse myeloma cell line 
Apoptosis was based on morphology, and mternucleosomal DNA fraginentat~on, 
studied in these cell lines 
A comparative study of cell cycle analysis and percentage of apoptosis was done for 
four p53-negative human leukemic cell lines 
Possibility of abrogation of apoptosis, was studied for Sp210, hybridoma, MOLT-4 
and Jurkat-J6 cell lines 
Drugs used in the present study : 
Fluoropyrim~dines are a group of drugs synthesized on a rational basls Three drugs of 
this group are 5-Fluorouracil (5-FU), 5-Fluorodexouridine (5-FdUrd) and 5-Fluorouridme 
(5-FUrd) 5-FU is an analog of uracil, where the hydrogen at the 5' carbon atom position 
In the pyrimidine ring 1s replaced by a fluorme The other fluoropyrimidines are 
derivatives with this susbstitut~on as the core basis of these drugs 
5-FU was the first to be synthesized in this group and has been used against a variety of 
neoplasia namely, cancer of colon, breast, GI tract, liver and other sol~d tumors The two 
~mportant modes of act~ons that this drug are the RNA and DNA directed cytotox~city 
DNA synthesis is inhibited 1Sy FdUMP (which is formed by actlvat~on of 5-FU w~thin the 
cell) which binds irreversibly to the key enzyme thyinidylate synthetase In case of RNA- 
directed cytotoxlcity, incorporation of 5-FU Into various species of RNA namely mRN& 
rRNA, tRNA and primer RNA can lead to altered structure and fimctlon of these RNAs 
5-FdUrd, the deoxyr~bonucleoside derivat~ve, has been commercially available for a 
number of years and IS primarily used for intra-arterlal infbsions 5-FdUrd acts as a 
substrate for both uridine and thymidine phosphorylases and can be converted to either 
FdUMP leading to thymidylate synthetase inhibition or yield 5-FU which in turn can go 
and get lncorporated into RNA Depending upon the dose, the cell type, and the enzymes 
involved In its activation, it will follow either of these pathways within the cells When 
the drug is known to cause cytotoxicity through thyinidylate synthetase inh~bition, it 
actually leads to uracil mlsincorporation mto DNA In turn causmg DNA damage 5- 
FdUrd 1s also considered a potent cell growth inhibitor The basis of 5-FdUrd cytotoxlcity 
is, to cause dNTP pool ~mbalances 
5-Furd (5-Fluorour~d~ne), the r~bonuelos~de der~vat~ve, acts as a substrate for uridme 
kmase to form FUMP to further get converted to FUTP and get incorporated Into RNA or 
y~eld 5-FU, once again, this depends upon the activity of the activation and converting 
enzymes, the cell type and the concentration of the drug itself 5-FUrd 1s known to 
med~ate ~ t s  toxrc~ty through ~ t s  mcorporat~on into actwe RNA synthes~s 
Methotrexate (MTX), 1s a clin~cally important antifolate that has been used and 
contmues to be used extensively in combinat~on w~th other chemotherapeutic agents In 
the treatment of mal~gnancies mcludmg acute lymphocytic leukem~a, osteosarcoma, 
carcinomas of the breast, head and neck, choriocarc~noma, non-Hodgkin's lymphoma, 
etc The efficacy depends on the rapid polyglutamylat~on and inhlbitlon of dihydrofolate 
reductase (DHFR), and the enzymatic pathways involved In DNA biosynthesis 
Cell Lines used : 
We have used the cell hnes which are p53 negative - human colon carcinoma cell line 
Colo320, human leukem~c cell lmes HLGO, K562, U937, MOLT-4, Jurkat-JG, CEM- 
CM3, a mouse leukemic cell lme wh~ch 1s p53 pos~t~ve - L1210, and a mouse myeloma 
cell line Sp210 
Exper~nzentnl procedure : 
Cell lmes were treated w~th the desired drug concentrat~ons for a period of 24 hours and 
observed for (a) morphological changes, (b) DNA fragmentation analys~s, and (c) Flow 
cytometry analysis of cell cycle perturbat~ons and percentage apoptosis 
Results : 
I Study of 5-Fluorouracil-induced apoptos~s: 
It has been observed that 5-FU mduced apoptosis was dose and time dependent, in all but 
K562 cells Th~s  particular cell lme seems to be drug resistant showing no apoptot~c 
morphology and DNA fragmentation HL-60 and COLO 320 fail to show morpholog~cal 
changes (and DNA fragmentat~on) except at 36 hour post drug-treatment MOLT-4 
showed "atypical" apoptotic morphology MOLT-4, U937 and Sp2/0 showed apoptotic 
DNA from 1pM drug concentrat~on onwards In all the cell lmes studled there was 
cons~derable heterogene~ty of morphological and DNA fragmentation However, the cell 
cycle analys~s howed a p~cture non-consistent with the morphology of K562, HL60 and 
U937 cell lmes whereas in case of MOLT-4 it was consistent w~th  the morpholog~cal 
observat~ons Overall, 5-FU caused growth arrest at the Go/Gl and S-phases of the cell 
cycle, showcasing its mechanism of lnh~biting active RNA synthesis and DNA synthes~s 
whlch varied according to the cell type The FACS analysis for percentage of apoptotlc 
cell population, was concurrent with the morphological picture for K562, HL-60 and 
MOLT-4 cell lines Differences In cellular response to 5-FU in the cell lines indicate that 
though this drug acts at G1/S boundry, the final outcome would depend on the rate of 
catabolism of this drug 
11 Study of 5-Fluorodeoxyur~dine-induced apoptosis : 
There 1s no part~cular type or pattern of apoptotic morphology that can be induced by 5- 
FdUrd, and in the present study it appears to be a dose and time dependent There is 
considerable heterogeneity on the apoptosls Inducing effect of the dmg, not only across 
the d~fferent cell lines but also withm the same cell line Mouse leukemic cell h e  L1210 
showed "atyp~cal" apoptot~c morphology 
Overall 5-FdUrd shows S-phase cytotoxicity It acts differently In d~fferent cell lmes 
w~thin the panel of human leukem~c cell lines The morphology and DNA fragmentation 
appears to be independent events in MOLT-4 and L1210 cell lmes There is no 
correlation between apoptotic morpholog~cal changes and the perturbations In the cell 
cycle phases In case of K562, U937 and HL60 cell lmes The most stnking drfference 
was observed in the cell line MOLT-4, where there are no apoptotic changes occuring 
what-so-ever at the morphology level However, there is sign~ficant chromatm 
condensation and DNA fragmentation taking- place w~thm the cell because this is 
observed as a slgnlficant Increase In the sub-GolG1 population of cells, apoptotic cells, 
compared to control 
II Study of 5-Fluorour~dine induced apoptosis : 
Overall, 5-FUrd causes apoptotic changes in almost all cell lines studled except K562 and 
COLO 320 There was a sign~ficant increase in apoptotic cells w ~ t h  increase in drug 
concentration L1210 cell lme shows an "atyp~cal" apoptotic morphology There 1s a 
difference In apoptotrc morphology In case of freshly cultured MOLT-4 cell h e  
compared to the extenswely sub-cultured MOLT-4 cell line, where the former shows the 
"atypical" apoptotic morphology There was cell cycle perturbation in each cell line, 
however each behaved In a different way, showlng that 5-FUrd does not cause 
cytotoxic~ty In all the cell lmes at G1/S-boundry as IS known from literature However it 
does show a picture consistent w~th  the literature that there is difference m the 
cytotoxic~ty depending on dosage of the drug and the cell type used, with the latter being 
more important a factor The general observation that emerges IS that the drug causes, an 
RNA-directed cytox~clty leadmg to apoptosis Overall, 5-FUrd showed acute cytotoxic~ty 
across all the cell lmes in the present study 
IV Study of Methotrexate induced apoptosis : 
Overall, the morphological, b~ochemical and flow cytometnc analyses of different cell 
types exposed to d~fferent concentrations of MTX indicated varylng degrees of cellular 
response In few cell llnes such as U937 and Sp210, MTX xs highly toxic, where as m cell 
line like MOLT-4, the drug is not effective enough to Induce morphological changes 
HL60 cells showed a response that is more or less intermediate between these two cell 
groups The heterogeneity of cellular response to MTX in these cell lmes can be 
attributed to the variation in cellular metabolism pertaming to MTX transport (influx and 
efflux), the relative ability to metabolize MTX into ~ t s  PGs and the individual cellular 
thresholds at which MTX-PGs cause folate inhibit~on 
V Study of inhib~tion of drug-induced apoptosls : 
DNA fragmentation analysis, In case of 5-FU induced apoptosis in mouse inyeloma cell 
line Sp210 which IS HGPRT negative, showed that neither thym~dine nor uridine 
indiv~dually or in comb~nat~on could rescue ~t from apoptosis While In case of MTX- 
mduced apoptosls of Sp210, it showed that neither hypoxanthine nor thymidine could 
inhibit MTX-mduced apoptosis In case of HGPRT positive hybridoma cell line we 
observed that both hypoxanthlne and thymidine when added individually could bring 
about ~ n h ~ b ~ t ~ o n  of 2pM MTX-induced apoptosls 
DNA fragmentation analysis, in case of 5-FU-mduced apoptosls In hybr~doma cell line 
showed that thyrn~dine at ImM could l n h ~ b ~ t  5-FU-~nduced apoptos~s at all the three drug 
concentrations, 0 1, 1 and lOpM of 5-FU Uridine at linM could mhibit 0 1 and lpM 5 -  
FU-mduced apoptosls However, lOmM of uridme could not mhlbit 10pM 5-FU-induced 
apoptosis These observat~ons md~cate that at h~gher drug concentration (101,1M 5-FU) the 
RNA-directed toxic~ty IS irreversible compared to the RNA-d~rected tox~city of lower 
drug concentrat~ons (0 1 and lpM 5-FU) 
In case of 5-FUrd induced apoptosis in human leukemic cell lines MOLT-4 and Jurkat- 
56, ~t was observed that uridme could rescue MOLT-4 cells from apoptosls when the drug 
concentration used was low (luM), whereas thymidine could not inhtb~t 5-FUrd induced 
apoptosis Jurkat-J6 cell lme could not be rescued from 5-Furd induced apoptosis e~ther 
by thymidine or uridine 
Conclusion : 
The variat~on in the apoptos~s inducmg capacltles of these drugs In different human 
leukemic cell lmes and the lnhlbit~on of apoptosls by exogenously added ur~dine and 
thymldme has opened avenues not only for understandmg basic cell b~ology, but also for 
study~ng anticancer effects of these drugs and for more effective use of these drugs for 
different types of cancers 
